Novacyt: Coronavirus Test Update

Novacyt announced an update regarding the novel coronavirus (COVID-19) test developed by Primerdesign, its molecular diagnostics division.

Following the completion of Public Health England’s (PHE) formal evaluation of Primerdesign’s COVID-19 test, as announced on March 12, 2020, the government agency has commenced ordering the test. Orders are initially for eight hospitals to provide stocks in those locations for four weeks of planned testing. The total value of the initial purchase is approximately £1.0 million (€1.1 million), which is the single largest order the Company has received to date for its COVID-19 test.

As of 13 March 2020, Primerdesign has sold and received orders for over £3.7 million (€4.3 million) of its CE-Mark and research use only (RUO) COVID-19 tests, which includes the order received from PHE. This represents approximately eight months of sales for the division under normal circumstances. This is additional revenue to the core Novacyt business.

Graham Mullis, Chief Executive Officer of Novacyt, commented: “We welcome Public Health England’s decision to use our COVID-19 test in the UK and I am delighted to see that Novacyt will now be supporting one of its home markets during these challenging times. The number of countries Novacyt is now supplying with its COVID-19 test has reached over 60 and we expect this will continue to increase. “The team at Novacyt and its key suppliers are working extremely hard to support clinicians around the world in the fight against this pandemic and, as a Chief Executive Officer, I am immensely proud of everyone’s commitment.”

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version